The plant is fully operational and designed to produce both mash and pelleted feed.
Lumpy skin disease is mainly insect-borne, causing fever, skin nodules, weakness and reduced milk production. It does not affect humans.
The partnership will help prove what millions of pet families already know: pets do not just make life better; they make us healthier.
The site is the company’s first ground-up factory in more than 50 years.
Critics warn that open-net farms could threaten wild salmon through escapes, disease and pollution.
The research will assess whether the technology can reduce virus levels in poultry environments while protecting bird health and production.
The site expansion bolsters Elanco’s monoclonal antibody (mAb) production; supports delivery of next-generation pipeline.
The project will repurpose a 463,503-square-foot fermentation facility at ADM’s Clinton complex.
The acquisition gives BiomEdit control of Folium’s Guided Biotics CRISPR-Cas technology and BiomElix One.
The facility is expected to open by the end of 2026.